Real estate
New markets are emerging, and a new report from the market research team at JLL pinpoints some of these growing areas.
As biopharma companies focus on efficiencies and close sites, jobs are getting lost. Here’s a look.
After Autolus Therapeutics’ backed out of its plan to establish a manufacturing center in Rockville, Maryland, Massachusetts-based TCR2 Therapeutics has stepped up to the plate to build an 85,000 square-foot cell therapy manufacturing facility in Rockville.
In 2019, Novartis subsidiary AveXis announced it acquired a manufacturing facility in Colorado to provide additional production capacity for Zolgensma. Just two years later, the facility will be closed and 400 people will be without a job.
Lyell Immunopharma announced this week that it has completed construction of a $65 million, 70,000-square-foot LyFE Manufacturing Center, which the company will use to support clinical trials and meet cell therapy manufacturing needs.
The investment made to build this end-to-end cell culture biopharmaceutical contract development and manufacturing organization facility clocked in at approximately $2 billion.
Merck KGaA is consolidating its Silicon Valley business/technology and materials innovations facilities under one 30,000-square-foot roof in San Jose, California, in an effort to boost their collaborative capacity for developing materials with biological applications.
Biogen plans to build a new gene therapy manufacturing plant in Research Triangle Park, North Carolina. The site is on the company’s manufacturing campus.
Beijing-based CRMO Pharmaron has accomplished impressive global growth via acquisitions over the past eight months.
The world’s first legal research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms (called shrooms or magic mushrooms) and other plant-based psychedelics recently opened in Jamaica.
PRESS RELEASES